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Background: Evasion of apoptosis is a hallmark of cancer cells. One mechanism to deregulate the apoptotic
pathway is by upregulation of the anti-apoptotic Bcl-2 family members. Navitoclax (ABT-263) is a Bcl-2/Bcl-xL
inhibitor that restores the ability of cancer cells to undergo apoptosis.
Methods: In this study we performed a high-throughput screen with 640 FDA-approved drugs to identify potential
therapeutic combinations with navitoclax in a non-small cell lung cancer (NSCLC) cell line.
Results: Other than a panel of cancer compounds such as doxorubicin, camptothecin, and docetaxel, four
antihelminthic compounds (benzimidazoles) potentiated navitoclax activity. Treatment with benzimidazoles led to
induction of the pro-apoptotic protein Noxa at the mRNA and protein level. Noxa binds and antagonizes antiapoptotic
protein Mcl-1. siRNA-mediated knock-down of Noxa completely rescued benzimidazole-potentiated navitoclax activity.
In addition, inhibiting caspase 3 and 9 partially rescued benzimidazole-potentiated navitoclax activity.
Conclusions: We have identified compounds and mechanisms which potentiate navitoclax activity in lung cancer cell
lines. Further validation of the benzimidazole-potentiated navitoclax effect in vivo is required to evaluate the potential
for translating this observation into clinical benefit.
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Evasion of apoptosis is a hallmark of cancer cells [1]. One
mechanism of apoptotic pathway deregulation is via upreg-
ulation of the anti-apoptotic Bcl-2 family members [2].
Apoptotic pathway proteins belong to a family of BH-
domain-containing proteins comprising three classes [3]: 1)
multi-domain anti-apoptotic (Bcl-2, Bcl-xL, Bcl-w, Bfl-1/
A1, and Mcl-1), 2) multi-domain pro-apoptotic (Bax, Bak),
and 3) BH3-only pro-apoptotic (Bid, Bim, Bad, Bik, Noxa,
Puma, Bmf, and Hrk). The BH3-only proteins contain a
single BH3 domain that interacts with specific anti-
apoptotic proteins [4]. For example, Bcl-2 and Bcl-xL bind* Correspondence: Lloyd.Lam@abbvie.com
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but not Bad protein. Other BH3 domain proteins such as
Bim and Puma are bound by all anti-apoptotic proteins.
Bax and Bak are the “effectors”. Once activated, they form
complexes and permeabilize the outer mitochondrial mem-
brane, resulting in the release of cytochrome c and other
pro-apoptogenic proteins to induce the cell death pathway.
Navitoclax (ABT-263) is a first-in-class Bcl-2 and Bcl-xL
antagonist that restores the ability of cancer cells to
undergo apoptosis [5]. It exhibits potent activity as a single
agent against several tumor types including small cell lung
cancer (SCLC) and hematological malignancies [6]. Resist-
ance to navitoclax in most solid tumors is due to its low
affinity to Mcl-1 [7,8]. In this regard, it was shown that
Mcl-1 could contribute to the overall resistance of SCLC
and other cancer cell lines to ABT-737, an analog of ABT-
263 [7-10]. Thus, combining agents that target Mcl-1 withis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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pressing high levels of Bcl-xL and Mcl-1 [11].
Multiple targeted agents have been shown to increase
the efficacy of ABT-737 through the modulation of Bcl-2
family proteins. One of the best known examples is CDK
inhibitors, which strongly decrease Mcl-1 expression and
overcome Mcl-1-dependent resistance to ABT-737 [8]. So-
rafenib has been shown to reduce Mcl-1 in hepatoma cells
in combination with ABT-737 [12]. Similarly, synergistic
induction of apoptosis by ABT-737 and imatinib mesylate
was observed in gastrointestinal stromal tumor cells [13].
Interestingly, EGFR inhibitors were shown to combine
with ABT-737 by inducing Bim [14,15]. Bim also plays a
role in combination of MEK inhibitors and ABT-263
[16,17]. Finally, bortezomib potentiates ABT-737 activity
by inducing Noxa, a BH3-only protein [18].
In this study we performed a high-throughput screen
with 640 FDA-approved drugs to elucidate mechanisms
for potentiation of navitoclax activity and to identify po-
tential therapeutic combinations. We reasoned that these
compounds have already undergone stringent testing for
safety and toxicity and could therefore accelerate the
process for clinical testing. From the screen, we identified
a class of antihelminthic compounds as potentiators of
navitoclax activity. Furthermore, we showed that the
mechanism of potentiation is via induction of Noxa. Our
results identify a novel combination regimen strategy for
improving navitoclax activity and support a viable hypoth-
esis for additional testing to assess the potential benefit of
this novel combination.
Results
Benzimidazoles identified as potentiators of navitoclax
activity
Navitoclax is a first-in-class Bcl-2 inhibitor with de-
monstrated antitumor activity against SCLC solid tumor
cell lines and hematologic malignancies such as chronic
lymphocytic leukemia (CLL) and other leukemias [7,19].
However, resistance to this compound has been described
[7,8]. To identify potential combination treatment regi-
mens with navitoclax, we screened a library of 640 FDA-
approved compounds in a NSCLC cell line, Hcc827,
previously shown to depend on both Bcl-xL and Mcl-1 for
survival [20]. Hcc827 cells were treated with the library in
the presence or absence of 1 μM navitoclax for 1 or 3 days
(Figure 1A). Since the compounds that potentiated navito-
clax activity identified from the 1- or 3-day screens were
very similar, we set a cut off of >25% cell death after co-
dosing with navitoclax for hits. Our initial screen iden-
tified 40 compounds that could potentiate the effect of
navitoclax. Of these, 18 are known cancer chemotherapeu-
tic agents (e.g., doxorubicin, camptothecin, and docetaxel),
consistent with results reported recently [21]. Subsequent
repeats confirmed 26 compounds as potentiators ofnavitoclax activity. Since 4 of 7 benzimidazoles belonging
to a class of antihelminthic compounds (albendazole,
mebendazole, oxibendazole, and oxfendazole) were found
to potentiate navitoclax activity in Hcc827 cells (Figure 1B),
we decided to study the activity of these compounds fur-
ther. Similar trends were observed in another NSCLC cell
line, H292 (Additional file 1: Figure S1). Albendazole and
mebendazole showed the strongest potentiation (Figure 1B).
In addition, these agents have been used clinically to treat
human alveolar echinococcosis, a lethal pulmonary hel-
minthic infection, with minimal side effects to the host
[22]. We therefore focused our studies further on these two
compounds.
Benzimidazole monotherapy and combination with navi-
toclax was assessed in three NSCLC cell lines, Hcc827,
H292 and H1993. Increasing concentrations of albenda-
zole or mebendazole and navitoclax were used to treat
these lines and viability was measured. Although these
compounds show toxicity against these cell lines (up to
around 50% at 10 μM), potentially due to their activity
against the tubulins (see Discussion), they were more ac-
tive when combined with navitoclax (Figure 1C, D, and E).
The EC50 for both albendazole and mebendazole shifted
from ≥30 μM to 1.11 μM in Hcc827 cells, and ~10 μM
to ≤0.5 μM in H292 and H1993 cells. Bliss analysis showed
strong synergism (Bliss score > 30) between albendazole or
mebendazole and navitoclax in all three lines, suggesting
these compounds strongly potentiated the activity of
navitoclax.
Noxa plays an important role in albendazole and
mebendazole-induced navitoclax activity in NSCLC cell lines
To identify the potential mechanisms whereby albendazole
and mebendazole potentiate navitoclax activity, we utilized
a small-scale functional genomics approach in which
multiple proapoptotic BH3 domain proteins (Puma, Bad,
Noxa, and Bim) were knocked down using siRNAs [23].
siRNAs that rescued the cells from the toxicity of albenda-
zole or mebendazole and navitoclax combinations could
serve to identify proteins involved in the underlying mech-
anism. We first tested the effect of these siRNAs in rescu-
ing the potentiation effect of albendazole or mebendazole
in Hcc827 cells. The levels of knockdown of Bim and
Noxa by siRNA are shown in Additional file 2: Figure S2.
Interestingly, only the silencing of Noxa led to a complete
rescue of Hcc827 cells from benzimadazole-navitoclax
combinations (Figure 2A and B). We confirmed this
finding in H292 cells (Figure 2C and D). These results
implicate Noxa as playing an important role in the ben-
zidimazoles’ potentiation of navitoclax activity.
To assess whether Noxa is the sole mechanism for
albendazole- and mebendazole- potentiation of navitoclax
activity, we performed a titration experiment in which in-





Figure 1 High-throughput screening of a FDA approved drug library identifies a class of antihelminthic benzimidazoles compounds that
potentiate the effect of navitoclax in NSCLC cell lines. (A) Schematic representation of high-throughput FDA approved compound library screen.
(B) Hcc827 cells were treated with the FDA approved drug library (640 compounds) in the presence or absence of 1 μM navitoclax. Four dilutions per
compound (0.78, 3.13, 12.5, and 50 μM) were tested. Of the 40 compounds from the initial screen, 26 were validated and a class of antihelminthic
benzimidazoles was chosen for further studies. Potentiation of navitoclax activity was calculated by % of cells remaining in the presence of these compounds
plus navitoclax vs.% of cells remaining in the presence of these compounds alone. Validating anti-helminthic benzimidazoles potentiate navitoclax effect in
three NSCLC cell lines. (C) Hcc827, (D) H292, and (E) H1993 cells were treated with increasing concentrations of albendazole or mebendazole in the
presence of navitoclax (0, 1, 2, and 4 μM). Viability was determined after 1 day. Data shown are representative of at least two independent experiments.





Figure 2 Benzimidazoles mediate navitoclax activity through Noxa in Hcc827 and H292 cells. Hcc827 cells were transfected with siRNA
against four BH3 domain proteins for 1 day before adding (A) albendazole (0.5 or 8 μM) or (B) mebendazole (0.5 or 8 μM) +/− 1 μM navitoclax.
Viability was determined after 1 day. H292 cells were transfected with siRNA against four pro-apoptotic BH3 domain proteins for 1 day before
adding (C) albendazole (0.5 or 2 μM) or (D) mebendazole (0.5 or 2 μM) +/− navitoclax. Viability was determined after 1 day. H292 cells were
transfected with siRNA against Noxa for 1 day before adding (E) albendazole (0 to 30 μM) or (F) mebendazole (0 to 30 μM) +/− navitoclax.
Viability was determined after 1 day. T-test was carried out to test the significance of the observed differences between 2 conditions. *P < 0.05.
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navitoclax. In the presence of the control siRNA and navi-
toclax, potentiation was produced by both albendazole and
mebendazole (Figure 2E and F). In contrast, in the presence
of the Noxa siRNA and navitoclax, the potentiation was
completely rescued even at pharmacologic concentrations
of these compounds. These results further suggest that
Noxa is the major mechanism mediating albendazole and
mebendazole potentiation of navitoclax activity.
An independent evaluation of the role of Noxa to po-
tentiate navitoclax activity was performed by assessing theinduction of Noxa mRNA and protein expression upon
albendazole and mebendazole treatment. We used a mul-
tiple branched DNA technique to measure the gene ex-
pression of Noxa, Bim, Puma, Mcl-1, and Bcl-xL in H292
cells treated with albendazole and mebendazole. This
sandwich nucleic acid hybridization assay can amplify the
signal without requiring enzymatic amplification of the
target RNA [24]. Only Noxa mRNA was induced upon
albendazole and mebendazole treatment (Figure 3A). In
addition, albendazole and mebendazole treatment leads to
induction of Noxa protein (Figure 3B). These data are
BA
Figure 3 Induction of Noxa mRNA and protein in H292 cells
treated with albendazole and mebendazole. (A) H292 cells were
treated with or without 10 μM albendazole or mebendazole for 1 day.
Cell lysate was prepared and Noxa, Bim, Puma, Mcl-1, Bcl-xL, and HPRT
mRNA was measured using a branched DNA assay. The expression of
these genes was normalized to HPRT control and no treatment control.
(B) H292 cells were treated with increasing concentrations (0–10 μl) of
albendazole and mebendazole for 2 days. Cell lysate was prepared and
resolved on a 12% SDS polyacrylamide gel and probed with anti-Bim,
anti-Noxa, and anti-Mcl-1. Antibody against actin was used as loading
control. Data shown are representative of two independent experiments.
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Noxa is the major mechanism in albendazole and meben-
dazole potentiation of navitoclax activity.
Caspases are proteases that “execute” apoptosis. To de-
termine whether caspase 3 and caspase 9 are involved in
the benzimidazoles’ potentiation of navitoclax activity, we
pre-incubated H292 cells with inhibitors to caspase 3 and
caspase 9 prior to treatment with albendazole or meben-
dazole and navitoclax. Figure 4 shows that both inhibitors
of caspase 3 and caspase 9 partially rescued H292 cells
from albendazole or mebendazole and navitoclax-induced
toxicity. These data suggested that caspase 3 and caspase
9 mediate albendazole and mebendazole potentiation of
navitoclax activity.
Mebendazole potentiates navitoclax killing in multiple
NSCLC cell lines
To expand our studies, we determined whether meben-
dazole can potentiate the effect of navitoclax in a larger
panel of NSCLC cell lines. Of the 26 NSCLC cell lines
tested, we found that potentiation was observed in 15lines (with at least two concentrations having >20% cell
death and one concentration having >25% cell death)
(Figure 5). We have tested cell lines of other tumor ori-
gins and found that multiple lines (e.g., MDA-MB-231,
Hcc1806, Ovcar4, and PC3) show strong synergistic re-
sponses to albendazole with navitoclax (Additional file 3:
Figure S3). Our findings suggest that combination with
albendazole and mebendazole may enhance activity of
navitoclax.
Discussion
We report the identification of a class of benzidimidazole
antihelminthic compounds (albendazole, mebendazole, oxi-
bendazole, and oxfendazole) which markedly potentiate the
activity of navitoclax in multiple NSCLC cell lines. In
addition, we provide evidence that the mechanism for po-
tentiation is through the induction of Noxa. Silencing the
expression of Noxa completely rescues the cells from the
effect of these combinations.
Benzimidazole compounds are commonly used and have
broad spectrum antihelminthic activity against round-
worms, tapeworms and flukes in animals and humans.
Their major activity is through binding to parasite-tubulin,
leading to inhibition of polymerization or assembly into
microtubules. Interestingly, recent studies suggested that
these compounds could be used in cancer treatments
[25-27]. The mechanism of anti-tumor activity is through
the binding of tubulin [28,29]. A phase I clinical trial using
albendazole showed that the compound was well tolerated
and the maximum tolerated dose was 2,400 mg per day
[30]. Myelosuppression was the main dose-limiting tox-
icity. Fatigue and mild gastrointestinal upset were the
other major adverse effects. Another study using a differ-
ent antihelminthic, flubendazole, shows that inhibition of
microtubule function occurs through a mechanism dis-
tinct from Vinca alkaloids and displays preclinical activity
in leukemia and myeloma [31], suggesting these com-
pounds may also be combined with classical antitubulins
in cancer treatment. Potential problems with developing
the antihelminthic compounds for cancer therapy include
the rapid metabolism of these compounds in the liver [30].
We chose to employ the FDA-approved drug library to
screen for potentiators of navitoclax activity. Our rationale
included the following elements: 1) these compounds have
already been tested for safety and efficacy and are approved
for use in humans; 2) the use of compounds with good
drug-like properties could accelerate the process of clinical
testing; and 3) such a screen may reveal novel activities of
these compounds that would not be identified otherwise.
Indeed, our studies revealed an unknown mechanism of
the antihelminthic compounds against cancer cells poten-
tially other than binding to tubulin. In particular, we found
that antihelminthic compounds can induce the expression
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Figure 4 Inhibitors of caspase 3 and 9 partially rescue benzimidazole-mediated navitoclax activity in H292 cells. H292 cells were pretreated
with caspase 3 and 9 inhibitors (50 μM) before adding (A) albendazole (0 to 30 μM) or (B) mebendazole (0 to 30 μM) +/− 0.5 μM navitoclax.
Viability was determined after 1 day. T-test was carried out to test the significance of the observed differences between 2 conditions. *P < 0.05.
Figure 5 Mebendazole potentiates navitoclax activity in multiple NSCLC cell lines. 26 NSCLC cell lines were treated with increasing
concentrations of mebendazole in the presence or absence of 1 μM navitoclax. Viability was determined after 1 day. Data are presented as
% potentiation in the presence of navitoclax.
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regulation in determining sensitivity to ABT-737 with
or without modulation of Mcl-1 [7,18,32-38]. Agents
that induce Noxa include chemotherapeutic agents
such as etoposide, vinblastine, paclitaxel, dacarbazine,
camtothecin, cisplatin, and targeted agents such as
bortezomib. Since these agents represent different sub-
classes of cancer agents, it is likely that multiple mech-
anisms are involved in regulating Noxa. Earlier studies
suggested that p53 is involved in Noxa regulation in
response to DNA damage [39]. However, cells lacking
p53 can activate Noxa in response to bortezomib
[40,41]. In this case Noxa expression is induced via
Myc [40]. In another study, the endoplasmic reticulum
(ER)-associated protein degradation (ERAD) inhibitor
Eeyarestatin I and bortezomib activate Noxa via elicit-
ing a stress response program that involves the activa-
tion of transcription factors ATF3 and ATF4, which
bind to the Noxa promoter. In addition, these agents
block ubiquitination of histone H2A to relieve its in-
hibition on Noxa transcription [42]. A recent study
showed that BH3 mimetics other than ABT-737 also
antagonize Mcl-1 by activating the ER stress response,
inducing ATF3, ATF4, and Noxa, which can then se-
quester Mcl-1 and inhibit its function [43]. How Noxa
is regulated by the benzimidazoles is not known. We
observed no correlation between p53 mutation status
and sensitivity to benzimidazole-navitoclax combina-
tions, suggesting that p53 does not regulate Noxa in
response to benzimidazoles (Additional file 4: Figure S4).
Treatment with these agents did not alter the expres-
sion of ATF3 or ATF4 in H292 and Hcc827 cells, sug-
gesting that induction of Noxa is not a response to ER
stress (data not shown). Further studies will be required
to dissect the mechanisms of Noxa induction in these
cells. It would be interesting to determine whether the
binding of benzimidazoles to tubulin leads to induction
of Noxa.
Conclusions
Our study shows that the benzimidazoles potentiate
navitoclax activity through induction of Noxa. These
data suggest that Noxa-inducing agents would be good
candidates to combine with navitoclax, consistent with
other studies [33-35,41]. In the future, in vivo studies
should be performed to validate our in vitro findings.
However, other benzimidazoles with better pharmaco-
kinetics would be required since albendazole and
mebendazole are rapidly metabolized in the liver [30]. In
addition, biomarker identification for patient selection
for such combination would dictate the success of these
findings. Nevertheless, the methods we report here are
broadly applicable for identification of new combination
therapies and novel mechanisms.Materials and methods
Reagents
Navitoclax was synthesized at AbbVie, Inc. (North
Chicago, IL). FDA-approved drug library was purchased
from Enzo (Farmingdale, NY). Albendazole, mebendazole,
oxibendazole, and oxfendazole were purchased from
Sigma (St. Louis, MO). All siRNA pools were purchased
from Dharmacon (Lafayette, CO). Noxa antibody was pur-
chased from Abcam. Bim and Mcl-1 antibodies were pur-
chased from Epitomics (Burlingame, CA). Caspase 3 and
caspase 9 inhibitors were purchased from SantaCruz Bio-
technology (Santa Cruz, CA). All the branched DNA re-
agents were purchased from Affymetrix (Santa Clara, CA).
Cell culture, transfection, and cell-based assays
All NSCLC cell lines (ATCC, Manassas, VA) were cultured
in RPMI (Invitrogen Corp., Grand Island, NY) supple-
mented with 10% fetal bovine serum (Invitrogen), 1% so-
dium pyruvate, 4.5 g/L glucose, and antibiotics (Invitrogen)
and were maintained in a humidified chamber at 37°C
containing 5% CO2. These cells were authenticated by
morphologic, cell proliferation, and Mycoplasma tests rec-
ommended in the ATCC Technical Bulletin No. 8 (2007).
siRNAs were introduced into the cells by reverse trans-
fection using Lipofectamine2000 according to manufac-
turer’s instructions (Invitrogen). Briefly, siRNAs were first
mixed with Lipofectamine2000 in Opti-MEM (Invitrogen).
Cells were added at 1.5 − 2.5 × 10^4 cells/ 100 μl in 96-
well tissue culture plates after 15 minutes. A final concen-
tration of 20 nM siRNA was used. The cells were then
grown in medium without antibiotic for 1 day before add-
ing navitoclax. Forty-eight hours after transfection, cells
were assayed for viability using CellTiter Glo Luminescent
cell viability assay according to the manufacturer’s pro-
tocol (Promega, Madison, WI). Statistical analysis was
carried out using Microsoft Excel to determine p value
(2-tailed) and p < 0.05 was indicated by * in the figures.
Western blot analysis
Cell lysates were prepared in RIPA buffer (Sigma) with
protease inhibitor cocktail (Roche). 30 μg of total protein
was resolved on a 12% SDS polyacrylamide gel and
probed with anti-Bim, anti-Noxa and anti-Mcl-1. Anti-
body against actin (Santa Cruz Biotechnology, Santa
Cruz, CA) was used as a loading control.
Branched DNA assay
Cell lysates were prepared in lysis mixture (Affymetrix,
CA) with proteinase K (Affymetrix, CA). Branched DNA
assay for Noxa, Bim, Puma, Mcl-1, Bcl-xL, and HPRT
was designed by Affymetrix and was performed accord-
ing to the manufacturer’s instruction. The expression of
these genes was presented after normalizing to HPRT
expression and no treatment control.
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molecule library
Hcc827 cells were plated overnight before adding the com-
pounds. Medium was added to the compound library im-
mediately before adding to the cells. The cells with or
without navitoclax treatment were added simultaneously
or sequentially. NSCLC cell line Hcc827 was screened with
four concentrations (0.78, 3.13, 12.5, 50 μM) of the FDA
approved compounds in the presence or absence of 1 μM
navitoclax for 1 or 3 days. Cells were assayed for viability
using CellTiter Glo Luminescent cell viability assay
according to the manufacturer’s protocol (Promega,
Madison, WI).
Further validation was performed in three NSCLC cell
lines with increasing concentration of benzimidazoles and
navitoclax. Synergistic activities of navitoclax and benz-
imidazoles were determined using the Bliss additivity model
[44], whereby the combined response C of both agents with
individual effects A and B is C =A + B – (A × B), where A
and B represent the fractional inhibition between 0 and 1.
Combined response scores greater than 15 were considered
synergistic; 0–15 were considered no interaction, and less
than −15 were considered antagonistic.Additional files
Additional file 1: Figure S1. Multiple antihelminthic benzimidazoles
potentiate navitoclax activity in H292 cells. H292 cells were treated with
increasing concentrations of four different benzimidazoles in the
presence or absence of 1 μM navitoclax. Viability was determined after
1 day.
Additional file 2: Figure S2. Levels of knockdown by Bim and Noxa
siRNA in Hcc827 and H292 cells. Hcc827 and H292 cells were transfected with
Noxa or Bim or control siRNA for 2 days. Cell lysate was prepared and resolved
on a 12% SDS polyacrylamide gel and probed with anti-Bim, anti-Noxa, and
anti-Mcl-1. Antibody against actin was used as a loading control.
Additional file 3: Figure S3. Antihelminthic compound albendazole
potentiates navitoclax activity in MDA-MB-231, Hcc1806, Ovcar4, and PC3
cells. MDA-MB-231, Hcc1806, Ovcar4, and PC3 cells were treated with
increasing concentrations of albendazole in the presence or absence of
1 μM navitoclax. Viability was determined after 1 day.
Additional file 4: Figure S4. No correlation between TP53 mutation
status and mebendazole sensitivity in a panel of NSCLC cell lines.Abbreviations
NSCLC: Non-small cell lung cancer; ER: Endoplasmic reticulum; ERAD: ER-
associated protein degradation.
Competing interests
All authors are employees of AbbVie. The design, study conduct, and
financial support for this research was provided by AbbVie. AbbVie
participated in the interpretation of data, review, and approval of the
manuscript.
Authors’ contributions
HZ and JX: Designed and performed experiments. JDL and AB: Conceived
experiments and wrote paper. LTL: Conceived, designed, performed
experiments and wrote paper. All authors read and approved the final
manuscript.Acknowledgements
We thank members of the BCL2 group for helpful discussion. We thank Ping
Han for excellent technical help and David Shalinsky for critical review of the
manuscript.
Received: 23 October 2014 Accepted: 19 December 2014
References
1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70.
2. Cory S, Huang DC, Adams JM. The Bcl-2 family: roles in cell survival and
oncogenesis. Oncogene. 2003;22:8590–607.
3. Reed JC, Doctor KS, Godzik A. The domains of apoptosis: a genomics
perspective. Sci STKE. 2004;2004:re9.
4. Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG, et al. Differential
targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows com-
plementary apoptotic function. Mol Cell. 2005;17:393–403.
5. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, et al. ABT-263:
a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res.
2008;68:3421–8.
6. Gandhi L, Camidge DR, Ribeiro de Oliveira M, Bonomi P, Gandara D, Khaira D,
et al. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in
patients with small-cell lung cancer and other solid tumors. J Clin Oncol.
2011;29:909–16.
7. Tahir SK, Yang X, Anderson MG, Morgan-Lappe SE, Sarthy AV, Chen J, et al.
Influence of Bcl-2 family members on the cellular response of small-cell
lung cancer cell lines to ABT-737. Cancer Res. 2007;67:1176–83.
8. Chen S, Dai Y, Harada H, Dent P, Grant S. Mcl-1 down-regulation potentiates
ABT-737 lethality by cooperatively inducing Bak activation and Bax
translocation. Cancer Res. 2007;67:782–91.
9. Keuling AM, Felton KE, Parker AA, Akbari M, Andrew SE, Tron VA. RNA
silencing of Mcl-1 enhances ABT-737-mediated apoptosis in melanoma:
role for a caspase-8-dependent pathway. PLoS One. 2009;4:e6651.
10. Tagscherer KE, Fassl A, Campos B, Farhadi M, Kraemer A, Bock BC, et al.
Apoptosis-based treatment of glioblastomas with ABT-737, a novel small
molecule inhibitor of Bcl-2 family proteins. Oncogene. 2008;27:6646–56.
11. Lin X, Morgan-Lappe S, Huang X, Li L, Zakula DM, Vernetti LA, et al. ‘Seed’
analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance
to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737. Oncogene.
2007;26:3972–9.
12. Hikita H, Takehara T, Shimizu S, Kodama T, Shigekawa M, Iwase K, et al.
The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses
growth of hepatoma cells in combination with sorafenib. Hepatology.
2010;52:1310–21.
13. Reynoso D, Nolden LK, Yang D, Dumont SN, Conley AP, Dumont AG, et al.
Synergistic induction of apoptosis by the Bcl-2 inhibitor ABT-737 and
imatinib mesylate in gastrointestinal stromal tumor cells. Mol Oncol.
2011;5:93–104.
14. Cragg MS, Kuroda J, Puthalakath H, Huang DC, Strasser A. Gefitinib-induced
killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be
enhanced by BH3 mimetics. PLoS Med. 2007;4:1681–9. discussion 1690.
15. Gong Y, Somwar R, Politi K, Balak M, Chmielecki J, Jiang X, et al. Induction
of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in
mutant EGFR-dependent lung adenocarcinomas. PLoS Med. 2007;4:e294.
16. Corcoran RB, Cheng KA, Hata AN, Faber AC, Ebi H, Coffee EM, et al. Synthetic
lethal interaction of combined BCL-XL and MEK inhibition promotes tumor
regressions in KRAS mutant cancer models. Cancer Cell. 2013;23:121–8.
17. Tan N, Wong M, Nannini MA, Hong R, Lee LB, Price S, et al. Bcl-2/Bcl-xL
inhibition increases the efficacy of MEK inhibition alone and in combination
with PI3 kinase inhibition in lung and pancreatic tumor models. Mol Cancer
Ther. 2013;12:853–64.
18. Okumura K, Huang S, Sinicrope FA. Induction of Noxa sensitizes human
colorectal cancer cells expressing Mcl-1 to the small-molecule Bcl-2/Bcl-xL
inhibitor, ABT-737. Clin Cancer Res. 2008;14:8132–42.
19. Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Khaw SL, et al.
Substantial susceptibility of chronic lymphocytic leukemia to BCL2
inhibition: results of a phase I study of navitoclax in patients with relapsed
or refractory disease. J Clin Oncol. 2012;30:488–96.
20. Zhang H, Guttikonda S, Roberts L, Uziel T, Semizarov D, Elmore SW, et al.
Mcl-1 is critical for survival in a subgroup of non-small-cell lung cancer cell
lines. Oncogene. 2011;30:1963–8.
Lam et al. Cancer Cell International  (2015) 15:5 Page 9 of 921. Chen J, Jin S, Abraham V, Huang X, Liu B, Mitten MJ, et al. The Bcl-2/Bcl-XL/
Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic
agents In vitro and In vivo. Mol Cancer Ther. 2011;10:2340–9.
22. Vuitton DA. Benzimidazoles for the treatment of cystic and alveolar
echinococcosis: what is the consensus? Expert Rev Anti Infect Ther.
2009;7:145–9.
23. Lopez H, Zhang L, George NM, Liu X, Pang X, Evans JJ, et al. Perturbation of
the Bcl-2 network and an induced Noxa/Bcl-xL interaction trigger mitochondrial
dysfunction after DNA damage. J Biol Chem. 2010;285:15016–26.
24. Flagella M, Bui S, Zheng Z, Nguyen CT, Zhang A, Pastor L, et al. A multiplex
branched DNA assay for parallel quantitative gene expression profiling.
Anal Biochem. 2006;352:50–60.
25. Mukhopadhyay T, Sasaki J, Ramesh R, Roth JA. Mebendazole elicits a potent
antitumor effect on human cancer cell lines both in vitro and in vivo. Clin
Cancer Res. 2002;8:2963–9.
26. Pourgholami MH, Woon L, Almajd R, Akhter J, Bowery P, Morris DL. In vitro
and in vivo suppression of growth of hepatocellular carcinoma cells by
albendazole. Cancer Lett. 2001;165:43–9.
27. Doudican N, Rodriguez A, Osman I, Orlow SJ. Mebendazole induces
apoptosis via Bcl-2 inactivation in chemoresistant melanoma cells. Mol
Cancer Res. 2008;6:1308–15.
28. Sasaki J, Ramesh R, Chada S, Gomyo Y, Roth JA, Mukhopadhyay T. The
anthelmintic drug mebendazole induces mitotic arrest and apoptosis by
depolymerizing tubulin in non-small cell lung cancer cells. Mol Cancer Ther.
2002;1:1201–9.
29. Chu SW, Badar S, Morris DL, Pourgholami MH. Potent inhibition of tubulin
polymerisation and proliferation of paclitaxel-resistant 1A9PTX22 human
ovarian cancer cells by albendazole. Anticancer Res. 2009;29:3791–6.
30. Pourgholami MH, Szwajcer M, Chin M, Liauw W, Seef J, Galettis P, et al.
Phase I clinical trial to determine maximum tolerated dose of oral
albendazole in patients with advanced cancer. Cancer Chemother
Pharmacol. 2010;65:597–605.
31. Spagnuolo PA, Hu J, Hurren R, Wang X, Gronda M, Sukhai MA, et al.
The antihelmintic flubendazole inhibits microtubule function through a
mechanism distinct from Vinca alkaloids and displays preclinical activity in
leukemia and myeloma. Blood. 2010;115:4824–33.
32. Hauck P, Chao BH, Litz J, Krystal GW. Alterations in the Noxa/Mcl-1 axis
determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737.
Mol Cancer Ther. 2009;8:883–92.
33. Zall H, Weber A, Besch R, Zantl N, Hacker G. Chemotherapeutic drugs
sensitize human renal cell carcinoma cells to ABT-737 by a mechanism
involving the Noxa-dependent inactivation of Mcl-1 or A1. Mol Cancer.
2010;9:164.
34. Weber A, Kirejczyk Z, Potthoff S, Ploner C, Hacker G. Endogenous noxa
determines the strong proapoptotic synergism of the BH3-mimetic ABT-737
with chemotherapeutic agents in human melanoma cells. Transl Oncol.
2009;2:73–83.
35. Li R, Zang Y, Li C, Patel NS, Grandis JR, Johnson DE. ABT-737 synergizes with
chemotherapy to kill head and neck squamous cell carcinoma cells via a
Noxa-mediated pathway. Mol Pharmacol. 2009;75:1231–9.
36. Miller LA, Goldstein NB, Johannes WU, Walton CH, Fujita M, Norris DA, et al.
BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill
melanomas through Noxa-dependent apoptosis. J Invest Dermatol.
2009;129:964–71.
37. Tahir SK, Wass J, Joseph MK, Devanarayan V, Hessler P, Zhang H, et al.
Identification of expression signatures predictive of sensitivity to the Bcl-2
family member inhibitor ABT-263 in small cell lung carcinoma and
leukemia/lymphoma cell lines. Mol Cancer Ther. 2010;9:545–57.
38. Carette JE, Guimaraes CP, Wuethrich I, Blomen VA, Varadarajan M, Sun C,
et al. Global gene disruption in human cells to assign genes to phenotypes
by deep sequencing. Nat Biotechnol. 2011;29:542–6.
39. Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T, et al. Noxa, a
BH3-only member of the Bcl-2 family and candidate mediator of
p53-induced apoptosis. Science. 2000;288:1053–8.
40. Nikiforov MA, Riblett M, Tang WH, Gratchouck V, Zhuang D, Fernandez Y,
et al. Tumor cell-selective regulation of NOXA by c-MYC in response to
proteasome inhibition. Proc Natl Acad Sci U S A. 2007;104:19488–93.
41. Perez-Galan P, Roue G, Villamor N, Montserrat E, Campo E, Colomer D. The
proteasome inhibitor bortezomib induces apoptosis in mantle-cell
lymphoma through generation of ROS and Noxa activation independent of
p53 status. Blood. 2006;107:257–64.42. Wang Q, Mora-Jensen H, Weniger MA, Perez-Galan P, Wolford C, Hai T, et al.
ERAD inhibitors integrate ER stress with an epigenetic mechanism to
activate BH3-only protein NOXA in cancer cells. Proc Natl Acad Sci U S A.
2009;106:2200–5.
43. Albershardt TC, Salerni BL, Soderquist RS, Bates DJ, Pletnev AA, Kisselev AF,
et al. Multiple BH3 mimetics antagonize antiapoptotic MCL1 protein by
inducing the endoplasmic reticulum stress response and up-regulating
BH3-only protein NOXA. J Biol Chem. 2011;286:24882–95.
44. Berenbaum MC. Criteria for analyzing interactions between biologically
active agents. Adv Cancer Res. 1981;35:269–335.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
